Correlates of serum matrix metalloproteinase-8 (MMP-8) concentrations in nondiabetic subjects without cardiovascular disease

Clinica Chimica Acta

Volumn 379, Issue 1-2, 2007, Pages 48-52

  Aquilante, Christina L ^a   Beitelshees, Amber L ^b   Zineh, Issam ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Cardiovascular; Matrix metalloproteinase 8; Metabolic syndrome

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN; NEUTROPHIL COLLAGENASE; TRIACYLGLYCEROL;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETICS; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; SMOKING;

ADULT; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 8; METABOLIC SYNDROME X; POLYMORPHISM, GENETIC; SMOKING;

EID: 33847657898     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2006.12.006     Document Type: Article

References (24)

1. Herman M.P., Sukhova G.K., Libby P., et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 104 (2001) 1899-1904
2. Galis Z.S., Sukhova G.K., Lark M.W., and Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94 (1994) 2493-2503
3. Kato R., Momiyama Y., Ohmori R., Taniguchi H., Nakamura H., and Ohsuzu F. Plasma matrix metalloproteinase-8 concentrations are associated with the presence and severity of coronary artery disease. Circ J 69 (2005) 1035-1040
4. Vernooy J.H., Lindeman J.H., Jacobs J.A., Hanemaaijer R., and Wouters E.F. Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest 126 (2004) 1802-1810
5. Demedts I.K., Brusselle G.G., Bracke K.R., Vermaelen K.Y., and Pauwels R.A. Matrix metalloproteinases in asthma and COPD. Curr Opin Pharmacol 5 (2005) 257-263
6. Vihinen P., Ala-aho R., and Kahari V.M. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 5 (2005) 203-220
7. Molloy K.J., Thompson M.M., Jones J.L., et al. Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation 110 (2004) 337-343
8. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
9. Wang H., Parry S., Macones G., et al. Functionally significant SNP MMP8 promoter haplotypes and preterm premature rupture of membranes (PPROM). Hum Mol Genet 13 (2004) 2659-2669
10. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
11. Fricker J. MMP-8: a new target for atherosclerosis?. Drug Discov Today 7 (2002) 86-88
12. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
13. Mensah G.A., Mokdad A.H., Ford E., et al. Obesity, metabolic syndrome, and type 2 diabetes: emerging epidemics and their cardiovascular implications. Cardiol Clin 22 (2004) 485-504
14. Moller D.E., and Kaufman K.D. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 56 (2005) 45-62
15. Reilly M.P., and Rader D.J. The metabolic syndrome: more than the sum of its parts?. Circulation 108 (2003) 1546-1551
16. Park Y.W., Zhu S., Palaniappan L., Heshka S., Carnethon M.R., and Heymsfield S.B. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 163 (2003) 427-436
17. Koh K.K., Han S.H., and Quon M.J. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol 46 (2005) 1978-1985
18. Festa A., D'Agostino Jr. R., Howard G., Mykkanen L., Tracy R.P., and Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102 (2000) 42-47
19. Frohlich M., Imhof A., Berg G., et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 23 (2000) 1835-1839
20. Eckel R.H., Barouch W.W., and Ershow A.G. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on the pathophysiology of obesity-associated cardiovascular disease. Circulation 105 (2002) 2923-2928
21. Marx N., Froehlich J., Siam L., et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 23 (2003) 283-288
22. Perlstein T.S., and Lee R.T. Smoking, metalloproteinases, and vascular disease. Arterioscler Thromb Vasc Biol 26 (2006) 250-256
23. Malemud C.J. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 11 (2006) 1696-1701
24. Lijnen H.R. Metalloproteinases in development and progression of vascular disease. Pathophysiol Haemost Thromb 33 (2003) 275-281